We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-18.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$626M
AUM Growth
-$126M
(-17%)
Cap. Flow
+$63M
Cap. Flow
% of AUM
10.07%
Top 10 Holdings %
Top 10 Hldgs %
43.21%
Holding
89
New
9
Increased
11
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omeros
OMER
|
+$24.5M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$14.8M |
| 3 |
Rockwell Medical
RMTI
|
+$10.1M |
| 4 |
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
|
+$8.75M |
| 5 |
Heron Therapeutics
HRTX
|
+$8.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$41.8M |
| 2 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$8.24M |
| 3 |
Neurogene
NGNE
|
+$1.5M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$784K |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$627K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVCT.WS
76
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
| $686K | 0.11% |
2,200,000
| – | – |
|
77
Galectin Therapeutics
GALT
$203M
| $670K | 0.11% |
286,200
| – | – |
|
|
BITI
78
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
| $655K | 0.1% |
50,000
| – | – |
|
79
Veracyte
VCYT
$3.71B
| $647K | 0.1% |
137,990
| – | – |
|
|
NSTG
80
DELISTED
NanoString Technologies, Inc.
NSTG
| $640K | 0.1% |
40,000
-40,000
| -50% | -$627K |
|
|
ADAP
81
DELISTED
Adaptimmune Therapeutics
ADAP
| $299K | 0.05% |
25,000
| – | – |
|
|
CLLS
82
Cellectis
CLLS
$281M
| $298K | 0.05% |
11,300
| – | – |
|
|
AGTC
83
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $225K | 0.04% |
17,110
| – | – |
|
|
84
CALL
Heron Therapeutics
HRTX
$95.5M
| $100K | 0.02% |
+5,000
| New | +$167K |
|
|
KERX
85
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-826,000
| Closed | -$8.24M |
|
|
RCPT
86
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| – | – |
-220,000
| Closed | -$41.8M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, Cormorant Asset Management held 89 positions worth $626M, down 17% from $752M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Cormorant Asset Management deployed $63M of net new capital in Q3 2015, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Sage Therapeutics: 240,000 shares worth $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier.
On the sell side, the largest reduction was Neurogene, an estimated $1.5M trimmed.
- Cormorant Asset Management's largest Q3 2015 buy was Sage Therapeutics: 240,000 shares worth $10.2M.
- Cormorant Asset Management added most to Omeros in Q3 2015, an estimated $24.5M increase.
- Cormorant Asset Management's biggest Q3 2015 reduction was Neurogene, cutting an estimated $1.5M.
- Cormorant Asset Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $41.8M.
- Cormorant Asset Management's ten largest holdings make up 43% of its $626M portfolio in Q3 2015.
- Cormorant Asset Management opened 9 new positions and closed 2 in Q3 2015.
- Cormorant Asset Management's portfolio value fell 17% quarter-over-quarter to $626M.
Based on Cormorant Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.